Women's Health

New Yale University research offers reassurance for pregnant patients and their clinicians, although evidence of lasting structural damage remains a concern.

The research highlights the influence of hormonal changes on treatment selection and the need for more tailored, life stage–specific care.

Emerging data find buprenorphine in pregnancy matches methadone for autism and ADHD risk, supporting safer opioid MOUD access in pharmacy care.

PCOS in female athletes often goes unrecognized due to atypical presentations, requiring careful differentiation, individualized management, and a multidisciplinary approach to protect both performance and long-term health.

Pharmacists guide women through updated menopause hormone therapy labels, rising demand, patch shortages, and personalized risk-benefit counseling.

A Response to “We Can Do Better: Educating on Perimenopause and Menopause Is a Good Thing,” Published in November 2025

FDA-approved elinzanetant offers stronger nonhormonal relief for menopausal vasomotor symptoms, with promising trial results and simpler liver monitoring.

WHO’s 2025 pregnancy diabetes guidance explains glucose monitoring, hemoglobin A1C targets, and metformin/insulin choices, with a focus on low-resource care.

Reevaluating menopause hormone therapy myths, risks, timing, and access.

Study links GLP-1 receptor agonists plus progestin to lower endometrial cancer risk, hinting at new prevention and treatment paths with fewer hysterectomies.

The label change removes boxed warnings of cardiovascular disease, breast cancer, and probable dementia from certain hormone replacement therapy products.

The Medications Optimizing Maternal Safety (MOMS) program offers vital support to pregnant patients through community pharmacies.

Recent research reveals no link between menopause hormone therapy and dementia risk, urging further studies to clarify its effects on cognitive health.

A study determined that lifestyle factors and comorbidities were more likely to be associated with the onset of diabetes.

Explaining megestrol acetate's dual role in managing symptoms and enhancing treatment efficacy for estrogen receptor–positive breast cancer.

The guidelines are believed to promote screening adherence by providing women with a more comfortable, accessible, and less stressful testing option.

Discover the latest FDA-approved treatments, including lumateperone for depression and elinzanetant for menopause symptoms, plus innovative health supplements.

Continuous glucose monitoring (CGM) significantly reduces the risk of high birth weight in babies born to mothers with gestational diabetes.

COVID-19 vaccination significantly lowers severe illness and preterm birth risks for pregnant individuals.

Pharmacists can educate patients about FluMist for at-home administration and opioid labeling changes.

The FDA-approved flibanserin represents the first and only once-daily oral pill for postmenopausal women with hypoactive sexual desire disorder.

The American Cancer Society updates cervical cancer screening guidelines, introducing self-collection options and new exit criteria to enhance accessibility and compliance.

GLP-1 receptor agonists expand treatment options for diabetes, weight loss, and more, showing promise in heart failure, kidney disease, and neuroprotection.